The Purple Sky Store
Men's Quarter Zip (Embroidered Purple Ribbon)
Men's Quarter Zip (Embroidered Purple Ribbon)
Couldn't load pickup availability
More than just a style staple, this quarter zip supports an important cause. 40% of all revenue from the Champion Spirit Support Quarter Zip goes to Sky Foundation, a non-profit that funds pancreatic cancer research, allowing every purchase to make an impact.
Made from 95% recycled polyester, 5% spandex for a lightweight, elastic feel
Fabric weight: 5.5 oz./yd² (186.48 g/m²) for all-day comfort
Athletic fit with self-fabric cuffs and waistband
Triple-needle stitch details for added durability at cuffs, waistband, shoulders, and back yoke
Heat-sealed neck label for a smooth finish
Share









Recent News
View all-
Phase 1/2 Trial Launches for Innovative Pancrea...
UCSF researchers begin testing novel TCR-T cell therapy targeting KRAS mutations in advanced pancreatic cancer. A new clinical trial at UCSF has opened to test a first-of-its-kind immunotherapy for advanced...
Phase 1/2 Trial Launches for Innovative Pancrea...
UCSF researchers begin testing novel TCR-T cell therapy targeting KRAS mutations in advanced pancreatic cancer. A new clinical trial at UCSF has opened to test a first-of-its-kind immunotherapy for advanced...
-
FDA Approves NALIRIFOX as First-Line Treatment ...
New frontline treatment offers hope with improved survival outcomes for advanced PDAC patients The U.S. Food and Drug Administration (FDA) has officially approved NALIRIFOX, a new frontline therapy for patients with metastatic...
FDA Approves NALIRIFOX as First-Line Treatment ...
New frontline treatment offers hope with improved survival outcomes for advanced PDAC patients The U.S. Food and Drug Administration (FDA) has officially approved NALIRIFOX, a new frontline therapy for patients with metastatic...
-
Immunotherapy for Pancreatic Ductal Adenocarcin...
Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest cancers, with a 5-year survival rate under 10%. Standard treatments like surgery and chemotherapy often fail because the cancer usually comes...
Immunotherapy for Pancreatic Ductal Adenocarcin...
Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest cancers, with a 5-year survival rate under 10%. Standard treatments like surgery and chemotherapy often fail because the cancer usually comes...